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Abstract 
The validity of the classification of non-affective and affective psychoses as distinct entities has been 
disputed, but despite calls for alternative approaches to defining psychosis syndromes, there is a dearth 
of empirical efforts to identify transdiagnostic phenotypes of psychosis. We aimed to investigate the 
validity and utility of general and specific symptom dimensions of psychosis cutting across 
schizophrenia, schizoaffective disorder and bipolar disorder with psychosis. Multidimensional item-
response modeling was conducted on symptom ratings of the Positive and Negative Syndrome Scale, 
Young Mania Rating Scale, and Montgomery-Åsberg Depression Rating Scale in the multi-centre Bipolar-
Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium, which included 933 patients 
with a diagnosis of schizophrenia (n=397), schizoaffective disorder (n=224), and bipolar disorder with 
psychosis (n=312).  A bifactor model with 1 general symptom dimension, 2 distinct dimensions of non-
affective and affective psychosis, and 5 specific symptom dimensions of positive, negative, disorganized, 
manic and depressive symptoms provided the best model fit. There was further evidence on the utility 
of symptom dimensions for predicting B-SNIP psychosis Biotypes with greater accuracy than categorical 
DSM diagnoses. General, positive, negative and disorganized symptom dimension scores were higher in 
African American vs. Caucasian patients. Symptom dimensions accurately classified patients into 
categorical DSM diagnoses. This study provides evidence on the validity and utility of transdiagnostic 
symptom dimensions of psychosis that transcend traditional diagnostic boundaries of psychotic 
disorders. Findings further show promising avenues for research at the interface of dimensional 
psychopathological phenotypes and basic neurobiological dimensions of psychopathology.  
  
 
Introduction 
The validity of categorical classification in psychiatry is disputed because the clinical and neurobiological 
boundaries between disorders are dubious1-17. Therefore, there have been calls for alternative approaches to 
psychiatric classification that are empirically- and psychometrically-informed through the investigation of 
neural and psychological mechanisms that transcend current syndromes18-20. Some projects address the 
shortcomings of classic psychiatric classification, such as the Research Domain Criteria (RDoC) framework that 
integrates many levels of information (from genes to self-report) to further our understanding of basic cross-
disorder dimensions of functioning6, 7, 21, 22. The Bipolar-Schizophrenia Network for Intermediate Phenotypes 
(B-SNIP)23, 24 addresses overlap across psychosis syndromes by examining a broad array of endophenotypes. 
Recently, the Hierarchical Taxonomy of Psychopathology (HiTOP) consortium has emerged as a research effort 
that quantifies disorders according to several levels of psychopathology, including spectra, syndromes and 
symptom components, and characterizes them dimensionally25. However, to date, evidence on the link 
between transdiagnostic dimensions of clinical phenotypes and basic brain-based biomarkers is limited. 
  
In psychosis, the overlap of symptoms across diagnostic categories is especially prevalent, which leads to high 
comorbidity as seen with schizophrenia, schizoaffective disorder, and bipolar disorder26, 27. While the 
Kraepelinian dichotomy regarded dementia praecox/schizophrenia and manic depression as distinct 
diagnostic entities, recent research has challenged this dichotomy4, 5 and places schizophrenia and bipolar 
disorder on a transdiagnostic psychosis spectrum4 with schizoaffective disorder as an intermediate diagnostic 
category23. This overlap may be a result of shared genetic and environmental etiological factors4, 28-30. Findings 
also show, however, non-shared genetic and environmental risks4, 28, 30, which supports the heterogeneity of 
psychotic disorders.  
 
  
 
There remains a dearth of empirical efforts to identify a transdiagnostic phenotype of psychosis. The 
pentagonal model with five dimensions of positive symptoms, negative symptoms, cognitive disorganization, 
mania, and depression has received support in previous factor-analytic work31. However, recent research has 
demonstrated evidence for a bifactor model with a general psychosis factor encompassing non-affective and 
affective symptoms in patients with schizophrenia, schizoaffective and bipolar disorder, as well as five specific 
psychosis dimensions of positive, negative, disorganized, manic and depressive symptoms4, 5. This model was 
found to better fit empirical symptom data than a pentagonal model4, 5 and a model allowing for distinct non-
affective and affective psychosis factors32. It provides support for a psychosis spectrum ranging from bipolar 
disorder to schizoaffective disorder to schizophrenia. Further, in this bifactor model, shared etiological factors 
may be associated with the general psychosis factor, whereas non-shared etiological factors could contribute 
to more specific psychosis dimensions4, 5. This approach could also hone the diagnostic process by placing 
patients broadly on the psychosis spectrum and using the specific symptom dimensions to classify patients 
into specific diagnoses4, 5. While initial support for the diagnostic utility of these dimensions has been found 
using the operational criteria system4, such transdiagnostic models and their diagnostic utility need to be 
further tested with more detailed measures of psychosis, mania, and depression and cross-validated across a 
large multisite consortium such as B-SNIP. This would allow for improved understanding of the utility of these 
dimensions not only for diagnosis in research and clinical care in the United States, but also in relation to basic 
neurobiological constructs such as the three recently identified B-SNIP psychosis Biotypes33 in an attempt to 
connect dimensional psychopathological phenotypes with neurobiological mechanisms12, 14, 25. 
 
Therefore, this study aimed to investigate transdiagnostic dimensions of psychosis spectrum disorders cutting 
across non-affective and affective psychotic symptoms in patients with schizophrenia, schizoaffective 
disorder, and psychotic bipolar I disorder using widely established measures for assessing psychosis, mania, 
and depression (i.e., PANSS, YMRS, MADRS) in the B-SNIP consortium. We aimed to investigate: 1) whether 
  
 
there is a general dimension of psychosis spectrum disorders underlying all affective and non-affective 
psychotic symptoms; 2) whether formation of a) specific symptom dimensions (positive, negative, 
disorganized, depressive and manic symptoms) and b) distinct dimensions of affective and non-affective 
psychosis is justified in addition to a general psychosis dimension; 3) associations of socio-demographic and 
clinical variables with general, affective, non-affective and specific symptom dimensions; and 4) the utility of 
these dimensions for classifying patients into a) categorical DSM diagnoses of psychotic disorders and b) the 
B-SNIP Biotypes. 
 
Method 
 
Sample 
This study used data collected as part of the multisite B-SNIP consortium the same diagnostic assessment 
methodology across psychotic disorders23. Specifically, patients with a diagnosis of schizophrenia, 
schizoaffective disorder, and psychotic bipolar disorder were recruited from five sites in the United States 
through regional advertising and from inpatient and outpatient clinics in 2008-201223. Patients were in a 
non-acute symptom state, clinically stable and provided informed consent.  
 
Measures 
Participants were assessed extensively for their socio-demographic and clinical characterization (including 
age, gender, ethnicity and DSM diagnosis) with a variety of instruments23, 24. In this study, the responses 
of three well-established diagnostic instruments were investigated: the Positive and Negative Syndrome 
Scale (PANSS), which is a 30-item clinical interview that measures the severity of psychotic symptoms on 
a scale of 1-7; the Young Mania Rating Scale (YMRS)34, a 11-item measure to assess manic symptoms; and 
  
 
the Montgomery-Åsberg Depression Rating Scale (MADRS)35, a 10-item measure to assess depressive 
symptoms. Social functioning was measured using the Birchwood Social Functioning Scale (SFS)36. 
 
Statistical analysis 
Multidimensional item response modeling was conducted with the mirt package of the R environment (i.e., 
the Metropolis-Hastings Robbins-Monro algorithm37) for model estimation. Model fit was examined using the 
Log-Likelihood (LL), the Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), and the 
Sample size-Adjusted BIC (SABIC)38. Better model fit is indicated with lower values than for the comparison 
model.  
 
Given there is no definite evidence on the factorial structure of the PANSS, we first analyzed symptom ratings 
on the PANSS only and compared 18 previously published factor solutions5. Based on the modeling strategy 
in our earlier study5, we estimated three alternative item response models based on previously reported factor 
solutions reported for the PANSS5 (see Figure S1 in the online data supplement): 1) a unitary (unidimensional) 
model with 1 general factor explaining all symptom ratings to reflect a general dimension of the psychosis 
spectrum (model A); 2) a pentagonal (multidimensional) model with correlated specific factors to reflect 
specific positive, negative, disorganized, depressive and manic symptom dimensions (model B, corresponding 
to the pentagonal model of psychosis31); and 3) a bifactor model with 1 general factor independent from 5 
uncorrelated (orthogonal) specific factors (model C; corresponding to the bifactor model in our earlier study5, 
39). Given the latter is a full likelihood method, data was assumed to be missing at random. 
 
Using the best-fitting model for the PANSS identified in this initial step, we next conducted the primary analysis 
to investigate general and specific symptom dimensions based on all measures for assessing psychosis, mania, 
and depression (i.e., PANSS, YMRS, MADRS) by comparing model A-C, additionally allowing for factor loadings 
  
 
for YMRS and MADRS items on the general factor as well as on specific manic and depressive symptom factors, 
respectively (Figure S2). To investigate whether formation of distinct dimensions for affective and non-
affective psychosis was justified in addition to 1 general dimension and 5 specific symptom dimensions, model 
comparison of the primary analysis further included: 4) a bifactor model with 1 general psychosis dimension, 
5 uncorrelated specific factors (positive, negative, disorganized, depressive and manic symptom dimensions), 
and 2 uncorrelated factors to reflect distinct dimensions of affective and non-affective psychosis (model D); 
and 5) a model with 5 uncorrelated specific factors (positive, negative, disorganized, depressive and manic 
symptom dimensions) and 2 uncorrelated factors (distinct affective and non-affective psychosis dimensions) 
but without a general factor (model E;32). To ensure stable model estimation, the prevalence of responses per 
category per item was set to be at least 10% of the sample. Due to low coverage in the more severe categories, 
responses were collapsed into three categories for the PANSS, YMRS and MADRS. 
 
The association of socio-demographic characteristics (i.e., age, gender, ethnicity), DSM diagnosis, and social 
functioning (as independent variables) with factor scores of general and specific psychosis dimensions (as 
outcome variables) were analyzed using linear regression. Last, multinomial Receiver Operating Characteristic 
(ROC) analysis40 were conducted in Stata version 1441 to investigate the extent to which factor scores of 
general, affective, non-affective and specific dimensions allow for accurate classification of patients into a) 
categorical DSM diagnoses of psychotic disorders and b) the B-SNIP Biotypes. 
 
Results 
Basic sample characteristics 
Basic characteristics of the total B-SNIP sample (n=933 patients) and the B-SNIP sample used for estimating 
item response models (n=860) were almost identical (see Table S1 in the online data supplement): the mean 
age at interview was 36 years and approximately half were male; the sample primarily consisted of patients 
  
 
with Caucasian or African American ethnicity; and the most common diagnosis was schizophrenia, followed 
by psychotic bipolar disorder and schizoaffective disorder.  
 
Dimensionality of psychotic disorders 
Initial analysis of symptom ratings on the PANSS indicated that a bifactor model with 1 general and 5 specific 
factors based on the PANSS 5-factor solution by Emsley et al.42 best matched the B-SNIP sample data 
(AIC=53209.8, BIC=53920.0, SABIC=53443.7) (Table S2 and S3), thereby, replicating our bifactor model in 
schizophrenia spectrum disorder5. Building on this initial step, we next compared item response models for 
symptom ratings on all measures for assessing psychosis, mania, and depression (i.e., PANSS, YMRS, MADRS; 
Figure S2). This showed that the bifactor model with general, non-affective, affective and 5 specific factors 
(i.e., model D) to reflect a general dimension of the psychosis spectrum (general factor), distinct dimension of 
non-affective and affective psychosis (non-affective and affective psychosis factors), and specific positive, 
negative, disorganized, depressive and manic symptom dimensions (5 specific factors) provided the best 
model fit as indicated by the lowest AIC, BIC and SABIC (AIC=65988.4, BIC=67201.4, SABIC=66391.6) compared 
with alternative models (Table 1). 
 
[Insert Table 1] 
 
Findings on the best-fitting model showed that the largest amount of item variance was explained by the 
general psychosis dimension (ωH =0.67) followed by negative (ωS=0.45), depressive (ωS=0.38) and positive 
(ωS=0.30) symptom dimensions (Table 2). Overall, factor loadings were heterogenous in magnitude across 
symptom dimensions. Factor loadings for the general psychosis dimension were moderate to strong for most 
positive, negative, disorganized, manic and depressive symptom ratings of PANSS and YMRS items, but weaker 
for MADRS items (Table 2). The non-affective psychosis dimensions showed the strongest factor loadings for 
  
 
negative and disorganized symptom ratings on the PANSS. Factor loadings for the affective psychosis 
dimension were strongest for MADRS depressive symptom ratings and, to a lesser extent, YMRS manic 
symptom ratings. Specific positive and negative symptom dimensions demonstrated moderate to strong 
factor loadings for most items of the PANSS, whereas factor loadings for the specific disorganized symptom 
dimension were only weak to moderate at most. Factor loadings for specific manic and depressive symptom 
factors were strongest for YMRS and MADRS, respectively.  
 
[Insert Table 2] 
 
Symptom dimensions by socio-demographic characteristics, social functioning, and DSM diagnosis 
Symptom profiles showed that, compared with psychotic bipolar disorder, factor scores on the general, non-
affective, affective, positive, negative, disorganized and depressive symptom dimensions were higher for 
schizoaffective disorder (all p<0.05) (Figure S3 and Table 3). By contrast, factor scores on the specific manic 
symptom dimension were lower for schizoaffective than psychotic bipolar disorder (p<0.001). Further, factor 
scores on the non-affective, positive, negative and disorganized symptom dimensions were higher, and factor 
scores on the affective and manic symptom dimensions lower, for schizophrenia than for psychotic bipolar 
disorder (all p<0.001). 
 
Table 3 further shows that factor scores for the general psychosis dimension were significantly higher for 
patients with African American than Caucasian ethnicity (p=0.001) and with lower social functioning (p<0.001). 
Further, factor scores for the non-affective psychosis dimension were lower in women (p<0.001) but higher in 
younger patients (p=0.001) and patients with lower social functioning (p=0.023). Factor scores for the affective 
psychosis dimension increased with increasing age (p=0.017) and were higher in female patients (p<0.001) 
and those with lower social functioning (p=0.020). Older patients had higher factor scores on specific positive 
  
 
and disorganized symptom dimensions. Female patients scored lower on the specific positive symptom 
dimension and higher on the specific depressive symptom dimension (all p<0.05). Compared with Caucasian 
patients, patients with African American ethnicity had higher factor scores on the positive, negative and 
disorganized symptom dimensions and lower scores on the depressive symptom dimension (all p<0.05). Social 
functioning decreased as scores on positive, negative, disorganized and depressive symptom dimensions 
increased, whereas social functioning increased with increasing scores on the manic symptom dimension (all 
p<0.05).  
 
[Insert Table 3] 
 
Utility of general, non-affective, affective and specific symptom dimensions 
When we examined the utility of symptom dimensions for classifying patients correctly into categorical DSM 
diagnoses of psychotic disorders using multinomial ROC analysis (Figure S4), this showed that the proportion 
of patients correctly classified into diagnostic categories based on factor scores of general, non-affective, 
affective and specific symptom dimensions (M=0.57, 95% CI 0.53-0.62) was higher compared with classifying 
patients by chance (M=0.39, 95% CI 0.33-0.44). 
 
We next examined the utility of symptom dimensions for accurately predicting the B-SNIP psychosis Biotypes. 
Figure 1 (and Table 3) shows high non-affective, positive, negative and disorganized symptom factor scores 
for Biotype 1, high affective, manic and depressive symptom factor scores for Biotype 3, and high general 
symptom dimension (and moderate other symptom dimension) factor scores for Biotype 2. There was 
evidence that the proportion of patients correctly classified into B-SNIP Biotypes based on factor scores of 
general, non-affective, affective and specific symptom dimensions (Figure S5a, M=0.41, 95% CI 0.35-0.47) was 
higher than what would be expected by chance (M=0.35, 95% CI 0.29-0.41); however, this did not hold for 
  
 
categorical DSM diagnoses (Figure S5b; DSM diagnoses, M=0.41, 95% CI 0.36-0.46; random accuracy, M=0.38, 
95% CI 0.31-0.44). As can be seen in Figure 2, findings on ROC curves further indicated that patients were 
classified into B-SNIP Biotypes with greater accuracy based on symptom dimensions (Figure 2a, AUC=0.87) 
than DSM diagnoses (Figure 2b, AUC=0.68). 
 
[Insert Figure 1 and 2] 
 
Discussion 
Main findings 
This study provides evidence on a transdiagnostic dimension underlying affective and non-affective psychotic 
symptoms in patients with psychotic disorder in the B-SNIP consortium. There was further evidence to suggest 
that formation of distinct dimensions of non-affective and affective psychosis as well as specific psychosis 
dimensions of positive symptoms, negative symptoms, disorganization, mania, and depression is justified. 
Transdiagnostic, non-affective, affective and specific symptom dimensions were differentially associated with 
age, gender, ethnicity, and social functioning and classified patients correctly into categorical DSM diagnoses. 
Finally, there was evidence on the utility of symptom dimensions for predicting the B-SNIP Biotypes with 
greater accuracy than DSM diagnoses. 
 
Methodological considerations 
In the current study, we examined the dimensionality of psychotic disorders in a large sample of patients 
with schizophrenia, schizoaffective and bipolar disorder with psychosis. This sample allowed for 
multidimensional item response modeling to identify variance driven by a transdiagnostic psychosis 
dimension independent from variance due to non-affective, affective and specific symptom dimensions 
based on symptom ratings using widely used and extensively studied measures of psychosis, mania, and 
  
 
depression (i.e., the PANSS, YMRS, and MADRS). While further sub-dimensions of mania, depression and 
other specific symptom dimensions (positive, negative and disorganized symptoms) may have been 
considered, the focus of the current study was on transdiagnostic, affective/non-affective psychosis and 
specific symptom dimensions, but not subcomponents of these (e.g. avolition as a subcomponent of the 
negative symptom dimension; euphoria as a subcomponent of mania or anhedonia as a subcomponent 
of depression). Models to account for these subcomponents would have been difficult to estimate even 
with the sample size obtained in this study given the high number of items required and free parameters 
to be estimated in such models. Further, a more stringent measurement design (e.g. a multitrait-
multimethod design) would have been required to disentangle measurement from substantive 
conceptual variance. The use of YMRS and MADRS as more detailed measures of mania and depression, 
however, did allow us to capture a broader spectrum of variance than would have been the case when 
using the PANSS alone and hence provided a better reflection of these specific symptom dimensions. They 
now need to be investigated further to disentangle method and substantive conceptual variance using 
comprehensive measures of psychopathology in large samples of psychotic disorders including psychotic 
depression. 
 
Comparison with previous research 
Evidence on a transdiagnostic dimension underlying affective and non-affective psychotic symptoms in the 
current sample of clinically stable patients is consistent with our earlier findings on such a dimension in 
patients with early and enduring psychosis4, 5. Reverberating the results of numerous previous studies31, 
including our own4, 5, we identified five specific symptom dimensions of positive symptoms, negative 
symptoms, disorganization, mania and depression. Our findings move beyond those from previous research 
in providing evidence of distinct non-affective and affective psychosis dimensions in addition to 
transdiagnostic and specific symptom dimensions. These were primarily characterized by negative and 
  
 
disorganized symptom ratings (for the non-affective dimension) and depressive and manic symptom ratings 
(for the affective dimension). According to the recently proposed hierarchical taxonomy of psychopathology25, 
the broad transdiagnostic psychosis dimension may best be interpreted at the level of psychopathological 
super-spectra or higher-order dimensions, whereas specific symptom dimensions may be may be classified at 
lower levels as symptom components, and non-affective and affective psychosis dimensions as 
psychopathological spectra or syndromes25. While the latter may resemble the previously reported thought 
disorder and internalizing dimensions2, the extent to which the transdiagnostic psychosis dimension overlaps 
with, or is independent from, a general psychopathology factor43 remains to be established. As the evidence 
base on the dimensionality of psychotic disorders continues to emerge and strengthen, the need for 
transdiagnostic investigations of psychotic and non-psychotic disorders becomes more pressing to examine 
important spectra or syndromes across disorders. 
 
Notably, our finding of higher factor scores on the positive, negative and disorganized symptom dimensions 
and lower scores on the depressive symptom dimension in patients with African American ethnicity compared 
with Caucasian patients is in line with earlier studies reporting higher positive44, 45, negative45 and 
disorganized44 symptom scores as well as lower depressive symptom scores 44 in patients with Black African 
compared with White Dutch and White British ethnicity in the Netherlands45 and the UK44, respectively. Our 
findings additionally showed that factor scores on the transdiagnostic psychosis dimension were higher for 
African American than Caucasian patients. Overall, the associations between transdiagnostic, non-affective, 
affective and specific symptom dimensions on the one hand, and age, gender, ethnicity and social functioning 
on the other, were broadly consistent with the clinical and social epidemiology of psychosis and, therefore, in 
support of their concurrent validity17, 46-49. 
 
  
 
These, however, need not only be valid but also useful.14 In order to elucidate the utility of the symptom 
dimensions we identified here, we investigated their accuracy for classifying patients into categorical DSM 
diagnoses and the B-SNIP psychosis Biotypes. Consistent with findings from our previous study4, overall, strong 
diagnostic utility of the transdiagnostic, non-affective, affective and specific symptom dimensions for 
allocating patients to DSM diagnoses was demonstrated with the PANSS, YMRS, and MADRS, which are all 
established clinical symptom measures that can be used in both research and routine care. Given our findings 
on symptom profiles by DSM diagnoses (Figure S3) were consistent with operational definitions of current 
classification systems, these may provide a basis for a psychometrically-informed approach for more accurate 
classification of patients into these diagnoses. When we examined the utility of symptom dimensions in 
relation to the recently identified B-SNIP Biotypes33, this showed patients were classified into these Biotypes 
with greater accuracy based on symptom dimensions than categorical DSM diagnoses. Findings further 
showed more pronounced non-affective (Biotype 1), affective (Biotype 3) and transdiagnostic (Biotype 2) 
dimensional symptom profiles for individual B-SNIP Biotypes (Figure 1). More generally, these findings show 
how dimensional psychopathological phenotypes can be characterized by connecting them to basic 
neurobiological constructs and, vice versa, offer valid dimensional psychopathological phenotypes to research 
into basic neurobiological dimensions of psychopathology such as RDoC12, 21, 22, 25. In other words, joining hands 
rather than viewing phenomenological and neurobiological approaches as separate or competing endeavors 
may be the way forward.  
 
Conclusions 
Our findings provide new evidence on the dimensionality of psychosis spectrum disorders and, specifically, 
suggest a transdiagnostic psychosis dimension, distinct non-affective and affective psychosis dimensions and 
5 specific symptom dimensions best account for symptom data collected using widely established measures 
in patients with schizophrenia, schizoaffective and bipolar disorder with psychosis. There was also strong 
  
 
evidence on the utility of these dimensions in relation to categorical DSM diagnoses and B-SNIP psychosis 
Biotypes. This should inform use of dimensional approaches in current diagnostic classification systems. 
Findings further show promising avenues for research at the interface of dimensional psychopathological 
phenotypes and other transdiagnostic approaches such as RDoC focusing on basic neurobiological dimensions 
of psychopathology1-17, 21, 22. This needs to be extended to transdiagnostic investigations of shared and non-
shared genetic and socio-environmental factors of symptom dimensions of psychotic and non-psychotic 
disorders to examine overlap (and independence) of important spectra or syndromes and more fully map and 
model the dimensionality of mental disorders as a basis for (more) valid diagnostic classification systems. 
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Tables 
 
Table 1. Model fit statistics for unitary (unidimensional), pentagonal (multidimensional), and bifactor models 
of psychosis based on PANSS, YMRS, and MADRS symptom ratings  
 LL FP AIC BIC SABIC 
Unidimensional (unitary) model (model A) -35660.2 153 71626.4 72354.2 71868.3 
Multidimensional (pentagonal) model with 5 
correlated specific factors (model B) 
-33615.3 163 67556.5 68331.9 67814.3 
Bifactor model with 1 general factor and 5 specific 
symptom factors (model C) 
-33253.0 204 66914.1 67884.5 67236.6 
Bifactor model with 1 general factor, 2 factors for 
non-affective and affective psychosis, and 5 specific 
symptom factors (model D) 
-32739.2 255 65988.4 67201.4 66391.6 
Bifactor model with 2 factors for non-affective and 
affective psychosis and 5 specific symptom factors 
(model E) 
-33372.9 204 67153.7 68124.2 67476.3 
Note: PANSS, Positive and Negative Syndrome Scale; YMRS, Young Mania Rating Scale; MADRS, Montgomery-Åsberg Depression Rating 
Scale; LL= Log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC, Sample size-Adjusted Bayesian 
Information Criterion. All response vectors with at least one response were analyzed (n=860). Responses to all three instruments 
recoded into three categories. Model D provides the best model fit as indicated by lower BIC, AIC and SABIC compared to other models 
 
  
  
 
Table 2.  Factor loadings in bifactor model with general, non-affective, affective, and 5 specific symptom factors based on PANSS, 
YMRS, and MADRS symptom ratings  
Items  General 
Non-
affective 
Affective 
Positive 
symptoms 
Negative 
symptoms 
Disorgani-
sation 
Mania Depression 
PANSS          
Delusions P1 0.55 0.22  0.75     
Hallucinatory behaviour P3 0.45 0.20  0.48     
Grandiosity P5 0.54 -0.00  0.20     
Suspiciousness P6 0.63 0.04  0.32     
Unusual thought content G9 0.55 0.34  0.53     
Lack of judgement and insight G12 0.48 0.32  0.15     
Blunted affect N1 0.09 0.69   0.44    
Emotional withdrawal N2 0.42 0.28   0.73    
Poor rapport N3 0.38 0.59   0.40    
Passive social withdrawal N4 0.30 0.16   0.80    
Lack of spontaneity N6 0.28 0.69   0.39    
Motor retardation G7 0.27 0.66   0.38    
Disturbance of volition G13 0.55 0.30   0.35    
Active social avoidance G16 0.50 0.02   0.71    
Conceptual disorganization P2 0.58 0.27    0.44   
Difficulty in abstract thinking N5 0.24 0.32    0.06   
Stereotyped thinking N7 0.61 0.40    0.46   
Mannerisms and posturing G5 0.55 0.50    0.20   
Disorientation G10 0.57 0.22    -0.11   
Poor attention G11 0.67 0.27    0.15   
Preoccupation G15 0.68 0.23    0.34   
Excitement P4 0.70  0.14    0.32  
Hostility P7 0.74  0.16    0.09  
Uncooperativeness G8 0.72  -0.07    0.07  
Poor impulse control G14 0.76  0.10    0.05  
Somatic concern G1 0.46  0.16     0.14 
Anxiety G2 0.52  0.38     0.39 
Guilt feelings G3 0.33  0.21     0.26 
  
 
Tension G4 0.64  0.22     0.17 
Depression G6 0.40  0.30     0.68 
YMRS          
Elevated mood 1 0.31  0.11    0.81  
Increased motor activity-energy  2 0.28  0.17    0.79  
Sexual interest 3 0.24  0.15    0.52  
Sleep 4 0.16  0.88    0.22  
Irritability 5 0.48  0.44    0.16  
Speech (rate and amount) 6 0.38  0.22    0.73  
Language - thought disorder 7 0.51  0.19    0.47  
Content 8 0.55  0.10    0.35  
Disruptive - aggressive behavior 9 0.63  0.22    0.27  
Appearance 10 0.26  0.07    0.16  
Insight 11 0.38  -0.11    0.12  
MADRS          
Apparent sadness 1 0.29  0.29     0.74 
Reported sadness 2 0.27  0.36     0.81 
Inner tension 3 0.39  0.52     0.38 
Reduced sleep 4 0.12  0.96     -0.03 
Reduced appetite 5 0.23  0.57     0.26 
Concentration difficulties 6 0.31  0.43     0.37 
Lassitude 7 0.24  0.36     0.56 
Inability to feel 8 0.30  0.39     0.55 
Pessimistic thoughts 9 0.27  0.41     0.60 
Suicidal thoughts 10 0.30  0.39     0.63 
ωH  / ωS  0.67 0.23 0.25 0.30 0.45 0.09 0.20 0.38 
Note: PANSS, Positive and Negative Syndrome Scale, YMRS, Young Mania Rating Scale, MADRS, Montgomery-Åsberg Depression Rating Scale, in n=860 patients, ωH / ωS, proportion of item variance  
explained by general, non-affective and affective factors (ωH) as well as specific factors (ωS) 
  
 
Table 3. Factors scores of general, non-affective, affective and specific symptom dimensions by socio-demographic and clinical variables 
  Latent factor scores 
 General  Non-affective  Affective  
Positive 
symptoms 
 
Negative 
symptoms 
 Disorganisation  Mania  Depression 
 B (95% CI, p)  B (95% CI, p)  B (95% CI, p)  B (95% CI, p)  B (95% CI, p)  B (95% CI, p)  B (95% CI, p)  B (95% CI, p) 
Age  
-0.00 (-0.01 – 0.00, 
0.167) 
 
-0.01 (-0.01 –  
-0.00, 0.001) 
 
0.01 (0.00 – 
0.01, 0.017) 
 
0.01 (0.00 – 
0.01, 0.010) 
 
0.00 (-0.00 – 
0.01, 0.282) 
 
0.01 (0.01 – 
0.01, <0.001) 
 
0.00 (-0.00 – 
0.01, 0.401) 
 
-0.00 (-0.01 – 
0.00, 0.356) 
Gender                
 Women vs. men  
0.09 (-0.04 – 0.22, 
0.156) 
 
-0.33 (-0.44 –  
-0.22, <0.001) 
 
0.26 (0.15 – 
0.38, <0.001) 
 
-0.16 (-0.27 –  
-0.05, 0.006) 
 
-0.02 (-0.14 – 
0.09, 0.683) 
 
-0.07 (-0.17 – 
0.03, 0.179) 
 
-0.02 (-0.13 – 
0.09, 0.684) 
 
0.22 (0.10 – 
0.34, 0.001) 
Ethnicity                
 
African American 
vs. Caucasian 
0.22 (0.09 – 0.35, 
0.001) 
 
0.05 (-0.08 – 0.17, 
0.456) 
 
-0.04 (-0.17 – 
0.08, 0.487) 
 
0.23 (0.11 – 
0.35, <0.001) 
 
0.16 (0.03 – 
0.29, 0.013) 
 
0.20 (0.09 – 
0.30, <0.001) 
 
0.00 (-0.11 – 
0.12, 0.977) 
 
-0.16 (-0.30 –  
-0.03, 0.017) 
 
Other vs. 
Caucasian 
0.02 (-0.24 – 0.28, 
0.855) 
 
0.00 (-0.24 – 0.24, 
0.976) 
 
0.02 (-0.22 – 
0.26, 0.858) 
 
0.22 (-0.02 – 
0.45, 0.071) 
 
0.12 (-0.12 – 
0.37, 0.325) 
 
0.06 (-0.14 – 
0.27, 0.554) 
 
-0.10 (-0.33 – 
0.13, 0.377) 
 
0.09 (-0.17 – 
0.35, 0.489) 
Social functioning 
-0.01 (-0.01 –  
-0.00, <0.001) 
 
-0.00 (-0.01 –  
-0.00, 0.023) 
 
-0.00 (-0.01 –  
-0.00, 0.020) 
 
-0.01 (-0.01 –  
-0.01, <0.001) 
 
-0.01 (-0.02 –  
-0.01, <0.001) 
 
-0.01 (-0.01 –  
-0.00, <0.001) 
 
0.01 (0.01 – 
0.01, <0.001) 
 
-0.01 (-0.01 –  
-0.00, <0.001) 
DSM psychosis 
diagnosis 
               
 
Schizoaffective vs 
bipolar disorder  
0.34 (0.17 – 0.50, 
<0.001) 
 
0.27 (0.13 – 0.41, 
<0.001) 
 
0.15 (0.01 – 
0.30, 0.042) 
 
0.87 (0.74 – 
1.00, <0.001) 
 
0.58 (0.43 – 
0.73, <0.001) 
 
0.46 (0.33 – 
0.58, <0.001) 
 
-0.30 (-0.48 – 
-0.15, <0.001) 
 
0.29 (0.13 – 
0.45, <0.001) 
 
Schizophrenia vs 
bipolar disorder 
0.06 (-0.09 – 0.21, 
0.417) 
 
0.70 (0.58 – 0.83, 
<0.001) 
 
-0.40 (-0.54 –  
-0.28, <0.001) 
 
0.75 (0.63 – 
0.87, <0.001) 
 
0.55 (0.42 – 
0.68, <0.001) 
 
0.53 (0.42 – 
0.64, <0.001) 
 
-0.24 (-0.37 – 
-0.12, <0.001) 
 
-0.08 (-0.22 – 
0.06, 0.286) 
B-SNIP biotypes                
 
Biotype 2 vs 
biotype 1 
0.16 (-0.01 – 0.34, 
0.070) 
 
-0.13 (-0.29 – 0.04, 
<0.132) 
 
0.19 (0.03 – 
0.35, 0.022) 
 
-0.09 (-0.25 – 
0.07, 0.283) 
 
-0.05 (-0.22 – 
0.12, 0.574) 
 -0.16 (-0.30 –   
-0.01 (-0.16 – 
0.15, <0.924) 
 
0.11 (-0.06 – 
0.29, <0.001) 
  
 
-0.01, 0.033) 
 
Biotype 3 vs 
biotype 1 
0.03 (-0.14 – 0.20, 
0.712) 
 
-0.37 (-0.53 –  
-0.22, <0.001) 
 
0.12 (-0.03 –  
-0.28, 0.117) 
 
-0.26 (-0.42 –  
-0.11, 0.001) 
 
-0.21 (-0.37 –  
-0.05, 0.010) 
 
-0.30 (-0.44 –  
-0.16, <0.001) 
 
0.02 (-0.12 – 
0.17, 0.751) 
 
0.13 (-0.04 – 
0.29, 0.129) 
 
 
 
  
 
Figures 
 
Figure 1. Symptom profiles by the B-SNIP biotypes  
 
 
 
 
 
 
  
 
Figure 2. ROC curves of transdiagnostic, non-affective, affective and specific symptom dimensions used in the prediction of B-SNIP biotypes and 
categorical DSM diagnoses. 
 
Figure 2a. ROC curves of symptom dimensions used in the    Figure 2b. ROC curves of categorical DSM diagnoses used in the 
prediction of B-SNIP biotypes      prediction of B-SNIP biotypes 
   
 
 
 
 
